Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of knee or hip osteoarthritis with history of pain at the reference joint for at least 3 months or clinical diagnosis of low back pain of benign origin for at least 3 months~* Must be dissatisfied with their current analgesic therapy (e.g. Non-steroidal anti-inflammatory drugs NSAIDS, COX-2 inhibitors, opioids, paracetamol/acetaminophen~* Have a pain intensity \>4 on Numerical Rating Scale~Exclusion Criteria:~* Life-long history of seizure disorder or epilepsy~* Any of the following within one year: mild/moderate traumatic brain injury, stroke, transient ischemic attack, and brain neoplasm~* Severe traumatic brain injury within 15 years (consisting of more than one of the following: brain contusion (injuries resulting in hemorrhage), intracranial hematoma, unconsciousness or post traumatic amnesia lasting for more than 24 hours) or residual sequelae suggesting transient changes in consciousness~* History of malignancy within past 2 years, with exception of a successfully treated basal cell carcinoma~* Presence of significant pain associated with conditions other than osteoarthritis or low back pain that could confound the assessment or self-evaluation of pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tapentadol (CG5503) (Type: EXPERIMENTAL): Tapentadol (CG5503) extended release (ER) 100 to 250 mg twice daily (BID) for up to one year.
- Oxycodone (Type: ACTIVE_COMPARATOR): Oxycodone controlled release (CR) 20 to 50 mg twice daily (BID) for up to one year.

Based on this trial design, predict the completion outcome and termination type (if applicable).